Skip to main content

Labcyte Closes $5.3M in Financing

NEW YORK (GenomeWeb News) – Labcyte has reeled in $5.3 million in Series D financing, which it plans to use to expand its acoustic low-volume liquid handling systems, the company said on Tuesday.

The new funding included backing from new investor GE Ventures' Heatlhymagination fund, and current investors, including Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors, and H&Q Life Sciences Investors.

Sunnyvale, Calif.-based Labcyte said its acoustic systems enable the transfer of very low volumes of liquids without the use of pipettes, lowering costs and reducing errors, and provide the capability to miniaturize assays, which can boost throughput and productivity.

"Our systems are being employed to further personalized medicine with multiple applications in genomics, proteomics, diagnostics and cell health," Labcyte CEO and President Mark Fischer-Colbrie said in a statement.

"Closing the funding will further enable us to add to our product lines and accelerate our growth," he said.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.